About PT-141 Medicine

What this site is

PT-141 Medicine is a reading room for the bremelanotide literature — the controlled trials, the approved label, and the access questions, summarized in plain English and cited line by line. No clinic operates here and no clinicians are on staff; the site diagnoses no one, prescribes nothing, and gives no medical advice. It is not a pharmacy or a vendor and sells nothing. It reads the record; it does not treat anyone.

The word "medicine" in our name describes the subject we cover — a medicine that has been studied and approved — and the editorial stance we take toward the literature. It is not a claim that this site offers treatment, consultation, prescriptions, or any clinical service. We occupy a reader's position relative to the research, nothing more.

How we work

Every quantitative claim on this site — every dose, percentage, effect size, half-life, and trial result — is tied to a numbered source on our references page, drawn from PubMed-indexed studies, the FDA prescribing information, and recognized monographs. We lead with what was measured and attribute it to its source. We separate three things readers often blur: what controlled trials found, what the approved label permits, and what the research-use community reports anecdotally. We keep those distinct on purpose.

What we are careful about

PT-141 (bremelanotide) is FDA-approved only for hypoactive sexual desire disorder in premenopausal women; we label every other use as off-label or investigational, because that is what the regulatory record shows. We recommend no dose to any individual and we name no commercial brands in our prose. Where the evidence is disputed — small effect sizes, a study under an Expression of Concern, debate over the diagnosis itself — we say so rather than smoothing it over. Honest framing is the whole point of the project.